Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study - Wikidata - wikimedia - TriplyDB

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

http://www.wikidata.org/entity/Q35023418

about

Targeting angiogenesis in gynecologic cancers The estrogen receptor joins other cancer biomarkers as a predictor of outcome Immunotherapy in endometrial cancer - an evolving therapeutic paradigm Contemporary use of bevacizumab in ovarian cancer Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas SHARP1 suppresses angiogenesis of endometrial cancer by decreasing hypoxia-inducible factor-1α level Fulvestrant for the treatment of endometrial cancer.Fool's gold, lost treasures, and the randomized clinical trial.A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer.Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.Therapeutic advances in women's cancers A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group study Chemotherapy Response Rates Among Patients With Endometrial Cancer Who Have Elevated Serum Platelets.Personalized therapy in endometrial cancer: challenges and opportunities.Molecular staging of gynecological cancer: What is the future?Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N Metformin: a modulator of bevacizumab activity in cancer? A case report A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up.NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know Integrative bioinformatic analyses of an oncogenomic profile reveal the biology of endometrial cancer and guide drug discovery.Expression of the Wnt antagonist Dickkopf-3 is associated with prognostic clinicopathologic characteristics and impairs proliferation and invasion in endometrial cancer.Aberrant NRP-1 expression serves as predicator of metastatic endometrial and lung cancers.Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines.A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.Molecular blockade of angiogenic factors: A new therapeutic tool for the treatment of abnormal uterine bleeding Personalized care in uterine cancer.The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.Strategies for Molecularly Enhanced Chemotherapy to Achieve Synthetic Lethality in Endometrial Tumors with Mutant p53 Current status of molecular-targeted drugs for endometrial cancer (Review).Recent Advances in Endometrial Cancer.Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.Oncolytic vaccinia virotherapy for endometrial cancer

P2860

Q26824766-D2BA2222-A79D-4F96-8860-E990AAF4D286 Q26865554-9CB9BB8A-65D6-496E-AF63-43F2C143BD97 Q27020910-A76CDC87-5F3B-4944-85ED-3510F98D872F Q27023510-F1EB8854-26DA-425D-BE1D-65368AB1CCFB Q28074769-CD6B0989-D3A5-4F09-93E7-96416259FAAF Q33740510-F5D4851B-1EA1-465D-8894-CF178AE0EC0F Q34514391-830D9D24-9506-4723-BD21-EFE3B0246324 Q34669260-70C2E124-7F49-4C28-A337-EE6FA2B27AB8 Q34781699-0D92BEE2-D254-4F1B-8242-BFBC36A30B27 Q34951783-BC7AAD2F-3368-4CF1-B414-7BA3F48D4AB2 Q35144264-B800E95D-6FE8-48EA-8B97-8345DF88C043 Q35180428-B35B5E8E-9DA8-4144-B94D-8DABD5F136D0 Q35216723-791CB66E-3130-4330-AEE0-6606A0462865 Q35418973-2FC048BD-3B34-45BE-9728-720CB12CCE89 Q35748507-0B40DE92-5FF7-48A8-A842-D834B7EF5019 Q35769337-8A086CC4-2D59-4118-85C1-91F1E5BF51A4 Q35911350-725C0362-8B68-4C44-9772-8C5FE1C8699C Q35940829-B43D5AC9-ABA5-479A-BC2C-D9C616CE05D7 Q36191443-F932B22A-41A6-43EF-820C-E9BC77B54EAA Q36214971-3807A1E6-4664-4D1C-9A0A-DD4C95DA136F Q36274386-09CA0DBB-BD45-4013-8255-D7D282825DD9 Q36372293-FD3B44E3-4086-47D8-AC87-6FD74D1B1497 Q36387267-56B22742-9CAB-4CC7-AC6D-CAD3705B71AD Q36407018-FD43315E-231A-4486-B8B6-CBF935623432 Q36598756-6075CD28-5A5B-4248-A17D-367DC763D27F Q36687666-AA85FC61-6BEC-4E8B-99F2-772E6946C1B8 Q36731185-495E8BC0-E9A7-49F3-BD63-0FE90E62B969 Q36905799-A420AADD-4A91-43A5-AEB5-559F3B34C696 Q36944293-ADC4C6CA-2F39-4287-A4DF-19ED70999C2B Q36946683-8B22AD61-C850-4470-967D-495F2B67F939 Q36959292-C0454960-924E-486A-A1AD-BF59A45D0BD3 Q36977417-F7F3BFD6-AE2C-4E32-B2D0-BB01B0551C57 Q36984349-3920B3AE-14B4-449F-831A-2A3E6D735AA1 Q37006856-B30CD195-F685-4E97-9A5B-1C9BD74098B4 Q37061044-F7C0D77F-423D-4D44-AF2A-88750ECAB119 Q37411955-C6BCAC1C-293B-4F90-A8FA-BC7EF29B83EF Q37560813-CBA6FC97-1CBE-4776-B076-BA854E43E850 Q37620470-75EAD82A-AD03-4797-B398-2A689BC6BD89 Q37625385-2A4553AB-3D8A-4C07-AB34-9145720DE017 Q37688850-DCAA4284-1111-412F-A0D8-446D26611558

P2860

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

http://www.wikidata.org/entity/Q35023418

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase II trial of bevacizumab ...... necologic Oncology Group study

@ast

Phase II trial of bevacizumab ...... necologic Oncology Group study

@en

type

label

Phase II trial of bevacizumab ...... necologic Oncology Group study

@ast

Phase II trial of bevacizumab ...... necologic Oncology Group study

@en

prefLabel

Phase II trial of bevacizumab ...... necologic Oncology Group study

@ast

Phase II trial of bevacizumab ...... necologic Oncology Group study

@en

P1433

Q35023418-875B2A36-150B-482D-9621-EA7EF9CB5F5A

P1476

Q35023418-B31CDA2B-F56B-412D-A553-2A10D3E89BD2

P2093

Q35023418-0765DDAA-8255-46F6-ACA8-E6EF2B0A6BB2

Q35023418-0FF762CD-D9B9-412E-ADB6-D4E24A64864E

Q35023418-2F9817B6-F799-4F84-AC5E-83D9A5412B3D

Q35023418-3843F1CB-1516-4AD8-8DAD-5EEAB048EC37

Q35023418-3E4E85DC-DFAF-4292-AD9D-7C726B586616

Q35023418-4C962995-F800-4D59-9F68-D8EFF3E9C41E

Q35023418-5573D6C3-C86C-4290-A77A-60C06E860F0C

Q35023418-7BDC6975-1069-434F-93E3-4194C0B07DC9

Q35023418-9BD17FB5-FAED-4EB4-B507-DEEBEFEB8DC4

Q35023418-C32734C4-FEF5-4FDC-B244-E28A71751E4E

P2860

Q35023418-0E263173-EE02-4811-8750-2FFA3B25A60F

Q35023418-12CBA013-E3F2-4B04-90BF-3F32F93413B2

Q35023418-1542C378-7D04-4134-B65F-5A219F9919F5

Q35023418-1CFEC80F-8250-4DDC-8300-8F1483AE6C93

Q35023418-2649B89D-0D04-4041-B4E7-A9B955D64A88

Q35023418-315F7916-4E36-41C6-A272-39A09DDCEEE9

Q35023418-355C9D99-DAE8-48BF-9061-943C35CC4CBC

Q35023418-413E2737-F5E0-4B45-B93F-B073CE70F562

Q35023418-44BFAB29-B65B-400E-90D7-EF88C01EB022

Q35023418-4ECE7C2F-C880-408D-A62F-A0ECDE6B1326

P304

Q35023418-A6FA523D-AF02-429F-8251-00903DE1F083

P31

Q35023418-8FE27C92-477C-4C11-968D-D17A675F8224

P3181

Q35023418-86F621C5-A186-4D6B-A53F-70497D05F346

P356

Q35023418-C91556BD-09EA-48DD-8925-1ACCABF450A9

P407

Q35023418-21933A51-E018-48FB-8C86-23BFF5A9D1FE

P433

Q35023418-5106E861-F7E1-4A46-8D59-DEBA743DF885

P478

Q35023418-FCD9B8B5-BABD-445B-BC00-D49873E71F78

P577

Q35023418-A57823CF-E1F7-480B-AB1C-9BA6CD8710B5

P698

Q35023418-41EC3534-3F37-42E5-A279-FE4684F9F1EA

P921

Q35023418-479B844D-1A30-4F04-BFD6-99C23A7AA108

Q35023418-C9DF064F-409B-4424-A5C1-9949B084C054

P932

Q35023418-C8701B73-8FF7-43C0-9091-2CF22E315EA9

P3181

P356

JCO.2010.32.6397

P1433

Journal of Clinical Oncology

P1476

Phase II trial of bevacizumab ...... necologic Oncology Group study

@en

P2093

Benjamin Greer

http://www.w3.org/2001/XMLSchema#string

Carol Aghajanian

http://www.w3.org/2001/XMLSchema#string

D Scott McMeekin

http://www.w3.org/2001/XMLSchema#string

Jacob Rotmensch

http://www.w3.org/2001/XMLSchema#string

Kathleen M Darcy

http://www.w3.org/2001/XMLSchema#string

Kimberly K Leslie

http://www.w3.org/2001/XMLSchema#string

Mack N Barnes

http://www.w3.org/2001/XMLSchema#string

Michael W Sill

http://www.w3.org/2001/XMLSchema#string

Parviz Hanjani

http://www.w3.org/2001/XMLSchema#string

Peter G Rose

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

Cancer statistics, 2010

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study.

A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.

P304

2259-2265

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

568

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2010.32.6397

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21537039

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3107744

http://www.w3.org/2001/XMLSchema#string